Welcome to our dedicated page for Oric Pharmaceuticals news (Ticker: ORIC), a resource for investors and traders seeking the latest updates and insights on Oric Pharmaceuticals stock.
ORIC Pharmaceuticals, Inc. develops clinical-stage oncology therapies designed to counter mechanisms of therapeutic resistance in cancer. News about ORIC commonly covers rinzimetostat (ORIC-944), a selective allosteric PRC2/EED inhibitor studied in prostate cancer and metastatic castration-resistant prostate cancer, and enozertinib (ORIC-114), a brain-penetrant selective inhibitor targeting EGFR exon 20 insertion mutations and EGFR atypical mutations.
Recurring updates include clinical and preclinical data presentations, development-dose decisions, oncology conference presentations, quarterly financial results, cash runway disclosures, at-the-market equity financing, and Nasdaq Rule 5635(c)(4) inducement equity grants.
ORIC Pharmaceuticals (Nasdaq: ORIC) granted equity awards to five new non-executive employees as material inducements to employment under Nasdaq Rule 5635(c)(4). On August 3, 2026, the company awarded 125,400 non-qualified stock options and 20,550 restricted stock units (RSUs) under its 2022 Inducement Equity Incentive Plan.
The stock options have an exercise price equal to ORIC’s closing share price on the grant date, with 25% vesting after one year and the remainder vesting monthly over the next 36 months. The RSUs vest in three equal annual installments over three years. According to ORIC, the Compensation Committee approved these grants pursuant to Nasdaq Rule 5635(c)(4).
ORIC Pharmaceuticals (Nasdaq: ORIC) reported second quarter 2026 results, highlighting advancement of its oncology pipeline and a solid cash position. The company initiated Himalayas-1, a global Phase 3 registrational trial of rinzimetostat in mCRPC, targeting about 600 patients across more than 250 sites in 25 countries.
ORIC entered a collaboration and supply agreement with Bayer, under which Bayer will provide NUBEQA (darolutamide) at no cost for the trial while ORIC retains full global rights to rinzimetostat. Cash, cash equivalents and investments totaled $387.6 million as of June 30, 2026, expected to fund operations into 2H 2028. Q2 2026 R&D expenses were $36.3 million and G&A expenses were $9.0 million, leading to a Q2 net loss of $41.5 million or $0.38 per share.
ORIC Pharmaceuticals (Nasdaq: ORIC) will feature three poster presentations at the ESMO Congress 2026 in Madrid, Spain, from October 23-27, 2026. The presentations cover enozertinib (ORIC-114) in treatment-naive metastatic NSCLC with EGFR atypical mutations and two posters on rinzimetostat in mCRPC.
The rinzimetostat presentations include a global Phase 3 Himalayas-1 trial-in-progress poster in patients previously treated with abiraterone and an ePoster on preclinical and patient sample data showing effects on luminal fate, AR signaling, and lineage plasticity. Full abstracts will be available on the ESMO website on October 19, 2026.
ORIC (Nasdaq: ORIC) announced initiation of Himalayas-1, a global Phase 3 registrational trial of rinzimetostat in metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone, and a clinical trial collaboration and supply agreement with Bayer for darolutamide (NUBEQA).
According to ORIC, Himalayas-1 will enroll about 600 patients across 250+ sites in 25 countries, randomizing patients 1:1 to receive 400 mg once-daily rinzimetostat plus darolutamide versus physician’s choice of an androgen receptor inhibitor or docetaxel. The primary endpoint is radiographic progression-free survival, with overall survival, PSA response rate, objective response rate, and patient-reported outcomes as key secondary endpoints.
Under the collaboration, ORIC will sponsor and conduct the trial, while Bayer will supply darolutamide at no cost. ORIC stated that Bayer receives no license or option rights to rinzimetostat and that ORIC retains full global development and commercial rights to the asset.
ORIC Pharmaceuticals (Nasdaq:ORIC) granted equity awards under Nasdaq Rule 5635(c)(4) to three new non-executive employees who started in June 2026. The July 1, 2026 grants include 44,400 stock options and 7,200 restricted stock units with multi-year vesting schedules tied to continued service.
ORIC Pharmaceuticals (Nasdaq: ORIC) granted equity awards under Nasdaq Rule 5635(c)(4) to two new non-executive employees who started in May 2026. On June 1, 2026, they received 34,800 stock options and 5,900 RSUs under the 2022 Inducement Equity Incentive Plan, with multi-year vesting schedules tied to continued employment.
ORIC Pharmaceuticals (Nasdaq: ORIC), a clinical-stage oncology company, will participate in two June 2026 investor conferences. Management joins fireside chats at the Jefferies Global Healthcare Conference on June 3 at 11:40 a.m. ET and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9 at 8:00 a.m. ET.
Both fireside chats, along with replays available for 90 days, can be accessed via webcasts in the investor section of ORIC’s website. Management will also hold one-on-one investor meetings at each event.
ORIC (Nasdaq: ORIC) reported Q1 2026 operational updates and cash of $419.7 million as of March 31, 2026. The company selected rinzimetostat 400 mg once daily as the RP3D with darolutamide for the Himalayas-1 Phase 3 in post-abiraterone mCRPC, expected to initiate in 1H 2026.
Rinzimetostat 400 mg showed mostly Grade 1 TRAEs, one Grade 3 TRAE, rare dose modifications, landmark rPFS of 93%, 84%, 84% at 3, 4, 5 months (median follow-up ~4.9 months), and PSA50 in 47% (7/15). Enozertinib Phase 1b enrollment completed for EGFR exon 20 insertion first-line; multiple 2H 2026 clinical updates expected.
ORIC Pharmaceuticals (Nasdaq:ORIC) granted inducement equity on May 1, 2026 to four new non-executive employees: 216,000 non-qualified stock options and 35,000 restricted stock units.
Options carry an exercise price equal to the closing price on May 1, 2026. Vesting: 25% after one year, then monthly 1/36th; RSUs vest one-third on each of the first three anniversaries. Grants were approved under Nasdaq Rule 5635(c)(4) and subject to plan terms and continued service.
ORIC (Nasdaq: ORIC) announced multiple poster presentations at the 2026 AACR Annual Meeting (April 2026) describing preclinical data for rinzimetostat (ORIC-944), an allosteric EED/PRC2 inhibitor for prostate cancer. Key findings: early and sustained PRC2 activity in prostate cancer, combination activity with darolutamide, and activity in PRC2-resistant models.
The posters report rinzimetostat's improved solubility, oral bioavailability, CYP profile, and clinical half-life versus comparators, plus retained activity where EZH1/EZH2 resistance is observed.